Evermay Wealth Management LLC purchased a new stake in Cencora, Inc. (NYSE:COR – Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 350 shares of the company’s stock, valued at approximately $85,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Fisher Asset Management LLC purchased a new stake in Cencora in the fourth quarter valued at about $244,000. Trust Co. of Vermont purchased a new stake in Cencora in the fourth quarter valued at about $62,000. Wahed Invest LLC acquired a new position in shares of Cencora in the fourth quarter valued at about $567,000. Vanguard Group Inc. acquired a new position in shares of Cencora in the fourth quarter valued at about $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new position in shares of Cencora in the fourth quarter valued at about $3,307,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the company. SVB Leerink reissued an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Citigroup increased their price objective on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Finally, Robert W. Baird increased their price objective on Cencora from $280.00 to $285.00 and gave the company an “outperform” rating in a report on Tuesday, July 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $238.78.
Insiders Place Their Bets
In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of Cencora stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The disclosure for this sale can be found here. Insiders sold a total of 1,899,112 shares of company stock valued at $408,654,376 over the last quarter. 15.80% of the stock is owned by insiders.
Cencora Stock Performance
Cencora stock traded up $1.13 during midday trading on Thursday, hitting $227.11. 969,411 shares of the company were exchanged, compared to its average volume of 1,363,092. The firm has a market capitalization of $45.30 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 1.56 and a beta of 0.45. Cencora, Inc. has a fifty-two week low of $171.65 and a fifty-two week high of $246.75. The business has a fifty day simple moving average of $226.85 and a two-hundred day simple moving average of $230.36. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89.
Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. The company had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. Cencora’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.50 earnings per share. On average, sell-side analysts forecast that Cencora, Inc. will post 13.46 earnings per share for the current year.
Cencora Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were given a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.90%. Cencora’s payout ratio is 22.32%.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
- Five stocks we like better than Cencora
- Stock Market Upgrades: What Are They?
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- The How And Why of Investing in Oil Stocks
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What Are the U.K. Market Holidays? How to Invest and Trade
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.